EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

June 29 2016 Adempas (riociguat) should not be used in patients with symptomatic pulmonary...

2015-16 flu vaccine effectiveness assessed in PHE report

2015-16 flu vaccine effectiveness assessed in PHE report

June 27 2016 The 2015-16 influenza vaccine effectiveness has been calculated at 57.6% in children...

Only fluoxetene considered of value in childhood major depressive disorder

Only fluoxetene considered of value in childhood major depressive disorder

June 15 2016 The bulk of commonly used antidepressants appear to have little value in the acute...

Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

May 11 2016 Initiating antiepileptic drug therapy in someone who has had a first unprovoked...

  • EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    Wednesday, 29 June 2016 10:44
  • 2015-16 flu vaccine effectiveness assessed in PHE report

    2015-16 flu vaccine effectiveness assessed in PHE report

    Tuesday, 28 June 2016 13:29
  • Only fluoxetene considered of value in childhood major depressive disorder

    Only fluoxetene considered of value in childhood major depressive disorder

    Wednesday, 15 June 2016 10:50
  • Final results from FLAME study confirms superiority of Ultibro Breezhaler over Seretide Accuhaler for reducing COPD exacerbations

    Final results from FLAME study confirms superiority of Ultibro Breezhaler over Seretide Accuhaler...

    Tuesday, 17 May 2016 12:01
  • Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

    Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

    Wednesday, 11 May 2016 11:32

vaccinationJune 27 2016

The 2015-16 influenza vaccine effectiveness has been calculated at 57.6% in children and young people aged 2 to 17 years. However, the vaccine effectiveness was 29.1% for adults aged over 65 years.

In its provisional end-of season results for the 2015-16 flu season, Public Health England said that overall influenza vaccine effectiveness was 52.4%, consistent with previous estimates. Vaccine effectiveness among younger adults (18-44 years) was 55.3%, and for those aged 45-64 years was 55.4%.

Children and young people had been given the vaccine by nasal spray (CNSV). PHE noted that “similar evidence of CNSV effectiveness has been reported in Finland, in contrast to the USA where it has been reported that CNSV has been less effective.”

PHE’s latest HPR newsletter points out that in the 2014-15 season when CSNV was piloted among primary school-aged children, “there was not only a 94% reduction in GP influenza-like illness consultation rates in the children themselves (and a 74% reduction in A&E respiratory attendances and a 93% reduction in hospital admissions among children) but also, in the same pilot areas, a 59% reduction in GP consultation rates for ILI in adults, compared to non-pilot areas.”

PHE will publish a fuller report on seasonal flu vaccine effectiveness later in 2016.

Links:

PHE Research and analysis HPR vol 10 issue 20 June 24

PHE Influenza vaccine effectiveness: 2015 to 2016 estimates

PHE provisional data summary

Clinical News

June 29 2016 New guidance for healthcare professionals to support pregnant women experiencing nausea and vomiting and hyperemesis gravidum have been published.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...